| Literature DB >> 30474936 |
Elke Platz1,2, Allison Merz2, Montane Silverman3, Eldrin Lewis2,4, John D Groarke2,4, Aaron Waxman2,5, David Systrom2,5.
Abstract
AIMS: Dyspnoea is common in heart failure (HF) but non-specific. Lung ultrasound (LUS) could represent a non-invasive tool to detect subclinical pulmonary congestion in patients with undifferentiated dyspnoea. METHODS ANDEntities:
Keywords: Congestion; Dyspnoea; Invasive haemodynamics; Lung ultrasound
Mesh:
Year: 2018 PMID: 30474936 PMCID: PMC6352886 DOI: 10.1002/ehf2.12381
Source DB: PubMed Journal: ESC Heart Fail ISSN: 2055-5822
Baseline characteristics by study group
| All subjects ( |
Control |
Congestion |
| |
|---|---|---|---|---|
| Age (years) |
68 (60, 74) | 62 (59, 70) | 70 (60, 77) | 0.38 |
| Women | 15 (60) | 7 (58) | 8 (62) | 1.00 |
| Race | 0.32 | |||
| White | 20 (80) | 11 (92) | 9 (69) | |
| Other | 5 (20) | 1 (8) | 4 (31) | |
| BMI (kg/m2) | 31 (25, 35) | 29 (25, 34) | 31 (27, 36) | 0.55 |
| Medical history | ||||
| Hypertension | 21 (84) | 11 (92) | 10 (77) | 0.59 |
| Diabetes | 5 (21) | 2 (17) | 3 (25) | 1.00 |
| Myocardial infarction | 4 (16) | 2 (17) | 2 (15) | 1.00 |
| CABG | 2 (8) | 1 (8) | 1 (8) | 1.00 |
| Sleep apnoea | 3 (13) | 2 (17) | 1 (8) | 1.00 |
| Heart failure | 8 (32) | 2 (17) | 6 (46) | 0.20 |
| Prior admission for heart failure | 4 (16) | 0 | 4 (36) | 0.09 |
| Atrial fibrillation/flutter | 7 (29) | 1 (8) | 6 (50) | 0.07 |
| COPD/asthma | 6 (24) | 4 (33) | 2 (15) | 0.38 |
| Ejection fraction (%) | 59 (50, 60) | 60 (55, 65) | 55 (46, 60) | 0.06 |
| Ejection fraction > 40% ( | 20 (91) | 10 (100) | 10 (83) | 0.48 |
| Medications | ||||
| ACE‐inhibitor/ARB | 13 (52) | 9 (75) | 4 (31) | 0.047 |
| Digoxin | 1 (4) | 1 (8) | 0 | 0.48 |
| Spironolactone | 4 (16) | 1 (8) | 3 (23) | 0.59 |
| Diuretic | 12 (48) | 4 (33) | 8 (62) | 0.24 |
| Calcium channel blocker | 9 (36) | 4 (33) | 5 (39) | 1.00 |
| Long acting nitrates | 4 (16) | 2 (17) | 2 (15) | 1.00 |
| Bronchodilator | 9 (36) | 4 (33) | 5 (39) | 1.00 |
| Laboratory results | ||||
| Sodium (mmol/L) ( | 140 (140, 142) | 142 (141, 142) | 140 (139, 140) | 0.036 |
| Creatinine (mg/dL) ( | 0.9 (0.9, 1.1) | 0.9 (0.8, 1.0) | 1.1 (0.9, 1.1) | 0.10 |
| Haemoglobin (g/dL) ( | 14 (12, 14) | 14 (12, 15) | 13 (12, 14) | 0.23 |
| NRS: Dyspnoea (range 0–10; 10 as worst) | ||||
| Dyspnoea at rest | 1 (0, 2.5) | 0.5 (0, 1.5) | 1.5 (0.5, 4) | 0.14 |
Continuous variables: median and inter‐quartile range (IQR) unless otherwise noted. Categorical variables: n, %.
ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blockers; BMI, body mass index; CABG, coronary artery bypass surgery; COPD, chronic obstructive pulmonary disease.
PCWP measured supine at rest.
Figure 1Mean B‐line number at rest by supine PCWP (n = 25). PCWP, mean pulmonary capillary wedge pressure.
Haemodynamics and lung ultrasound findings by study group
| Median (IQR) | All subjects ( | Control ( | Congestion ( |
|
|---|---|---|---|---|
| Supine (at rest) ( | ||||
| Heart rate (b.p.m.) | 70 (59, 80) | 60 (58, 81) | 74 (65, 78) | 0.34 |
| RA (mean; mmHg) | 7 (4, 10) | 4 (4, 6) | 10 (8, 12) | <0.001 |
| RV (end‐diastolic; mmHg) | 10 (6, 11) | 6 (4, 8) | 11 (11, 14) | <0.001 |
| PCWP (mean; mmHg) | 15 (9, 22) | 9 (7, 12) | 21 (18, 22) | — |
| PASP (mmHg) | 35 (26, 47) | 26 (23, 30) | 47 (41, 49) | <0.001 |
| mPAP (mmHg) | 24 (18, 31) | 18 (15, 21) | 31 (28, 33) | <0.001 |
| CO (L/min) | 5.1 (4.3, 5.7) | 5.6 (5.1, 6.0) | 4.4 (3.9, 4.9) | 0.022 |
| PVR (dyn * s/cm5) | 165 (106, 202) | 108 (89, 154) | 201 (158, 263) | 0.006 |
| Sitting (at rest) ( | ||||
| Heart rate (b.p.m.) | 66 (62, 81) | 74 (61, 100) | 67 (63, 78) | 0.68 |
| Systolic BP (mmHg) | 150 (138, 170) | 139 (131, 163) | 153 (138, 171) | 0.19 |
| Diastolic BP (mmHg) | 79 (67, 84) | 72 (65, 84) | 82 (68, 88) | 0.17 |
| SaO2 (%) | 96 (95, 97) | 97 (96, 98) | 96 (96, 97) | 0.60 |
| VO2 (mL/min) | 365 (281, 426) | 394 (293, 442) | 299 (281, 392) | 0.08 |
| RA (mean; mmHg) | 5 (3, 7) | 4 (3, 6) | 5 (4, 7) | 0.17 |
| PASP (mmHg) | 25 (21, 32) | 22 (20, 26) | 32 (23, 46) | 0.011 |
| mPAP (mmHg) | 17 (14, 24) | 15 (14, 18) | 23 (16, 33) | 0.019 |
| PCWP (mmHg) | 9 (6, 11) | 7 (6, 9) | 10 (9, 18) | 0.015 |
| CO (L/min) | 5.6 (4.1, 7.1) | 5.7 (4.5, 6.7) | 4.3 (3.5, 6.7) | 0.23 |
| PVR (dyn * s/cm5) | 156 (102, 239) | 116 (99, 175) | 181 (143, 260) | 0.10 |
| TPG (mmHg) | 10 (8, 13) | 8 (7, 11) | 11 (8, 14) | 0.13 |
| 8‐zone LUS 1 ( | ||||
| B‐lines (mean, SD) | 4.8 (5.6) | 2.6 (2.2) | 6.1 (6.6) | 0.37 |
| 2‐zone post. LUS 1 ( | ||||
| B‐lines (mean, SD) | 1.4 (2.0) | 0.9 (1.8) | 1.9 (2.2) | 0.13 |
| Sitting (peak exercise) ( | ||||
| Heart rate (b.p.m.) | 125 (110, 142) | 126 (116, 155) | 122 (86, 131) | 0.31 |
| Systolic BP (mmHg) | 190 (159, 202) | 200 (144, 235) | 185 (140, 204) | 0.24 |
| Diastolic BP (mmHg) | 88 (79, 94) | 85 (79, 91) | 91 (78, 100) | 0.55 |
| SaO2 (%) | 96 (95, 97) | 96 (96, 97) | 96 (94, 97) | 0.38 |
| VO2 (mL/min) | 1443 (985, 1611) | 1552 (1240, 1739) | 1285 (747, 1611) | 0.33 |
| VO2/kg | 15.4 (11.9, 18.3) | 16.9 (14.1, 18.3) | 15.8 (9.2, 19.7) | 0.65 |
| RA (mean; mmHg) | 8 (6, 10) | 6 (5, 8) | 10 (7, 13) | 0.05 |
| PASP (mmHg) | 51 (42, 59) | 45 (41, 50) | 59 (55, 69) | 0.003 |
| mPAP (mmHg) | 35 (27, 41) | 30 (27, 32) | 36 (35, 47) | 0.019 |
| PCWP (mmHg) | 17 (11, 26) | 14 (10, 16) | 24 (19, 28) | 0.005 |
| CO (L/min) | 10.8 (8.1, 13.3) | 11.9 (10.8, 13.3) | 9.5 (7.9, 13.5) | 0.20 |
| PVR (dyn * s/cm5) | 121 (89, 190) | 105 (89, 127) | 146 (98, 241) | 0.08 |
| TPG (mmHg) | 16 (14, 21) | 17 (14, 18) | 18 (15, 25) | 0.50 |
| 8‐zone LUS 2 ( | ||||
| B‐lines (mean, SD) | 3.8 (±6.0) | 2.1 (±1.5) | 5.4 (±8.3) | 0.94 |
| 2‐zone post. LUS 2 ( | ||||
| B‐lines (mean, SD) | 5.6 (±8.2) | 3.4 (±2.7) | 7.7 (±11.1) | 0.65 |
| Additional iCPET parameters ( | ||||
| Peak O2 pulse | 10 (8, 13) | 12 (8, 15) | 9 (8, 12) | 0.29 |
| Peak VE | 52 (35, 62) | 54 (46, 65) | 37 (34, 62) | 0.19 |
| VE/VCO2 slope | 34 (32, 36) | 34 (33, 35) | 34 (31, 36) | 0.89 |
CO, cardiac output; mPAP, mean pulmonary artery pressure; PASP, pulmonary artery systolic pressure; PCWP, mean pulmonary capillary wedge pressure; peak O2 pulse, amount of oxygen consumed per heart beat; PVR, pulmonary vascular resistance; RA, right atrial pressure; RV, right ventricular pressure; SaO2, arterial oxygen saturation; TPG, transpulmonary gradient; VE/VCO2 slope, minute ventilation/carbon dioxide production relationship; VE, minute ventilation; VO2, peak oxygen uptake.
Figure 2(A) Scatterplot of B‐line number by PCWP at rest. PCWP, mean pulmonary capillary wedge pressure. (B) Scatterplot of B‐line number by PASP at rest. PASP, pulmonary artery systolic pressure.
Spearman correlation between B‐lines and haemodynamics
| Rho ( | |||
|---|---|---|---|
| LUS 1 and supine haemodynamics (at rest; | LUS 1 and sitting haemodynamics (at rest; | LUS 2 and sitting haemodynamics (peak exercise; | |
| SaO2 | — | −0.16 | −0.15 |
| VO2 | — | 0.14 | −0.65 (0.002) |
| VO2/kg | — | — | −0.64 (0.002) |
| RA | 0.16 | 0.06 | −0.11 |
| PASP | 0.41 (0.043) | 0.46 (0.020) | 0.09 |
| mPAP | 0.40 (0.049) | 0.42 (0.034) | 0.08 |
| PCWP | 0.42 (0.039) | 0.54 (0.005) | 0.01 |
| CO | 0.04 | −0.06 | −0.58 (0.007) |
| PVR | 0.26 | 0.28 | 0.39 |
| TPG | — | 0.36 | 0.21 |
CO, cardiac output; mPAP, mean pulmonary artery pressure; PASP, pulmonary artery systolic pressure; PCWP, mean pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RA, right atrial pressure; SaO2, arterial oxygen saturation; TPG, transpulmonary gradient; VO2, peak oxygen uptake.
Only P values < 0.05 are shown. All other P values are non‐significant.